CancerPACE-CRCNCT07182773
Pre-infusion Aerobic Cycling Exercise for CardioRespiratory Fitness in Cancer Patients
A study testing Exercise in people with Cancer, run by University of Dublin, Trinity College at 1 site in Ireland.
Trial summary
Background to this Research Patients who undergo cancer treatment involving chemotherapy or immunotherapy, can experience considerable reductions in their fitness levels. This is a concern, as exercise is a really important part of cancer care. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer
- What is being tested?
- Exercise
- Type of treatment
- Injection or infusion, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 1 siteIreland
- Study dates
- 24 Sep 2025to Sep 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Aged >18.
- Histological confirmed diagnosis of stage I to IIIc breast, ovarian, or colorectal cancer.
- Scheduled to receive chemotherapy ± immunotherapy with curative intent over at least a 12-week period.
- Medical clearance from oncologist to partake in regular exercise in accordance with ACSM preparticipation screening algorithm.
- Able to use exercise bike independently.
- Ability to provide written informed consent.
Who cannot join
- Advanced/metastatic disease.
- Scheduled to receive concurrent chemoradiotherapy.
- New pain or other pain that would preclude ability to use bike.
- Inability to read and understand English.
- Deemed unfit to proceed from results of CPET.
- Unstable angina, arrhythmia, hypertension or decompensated heart failure.
Show all 10Show fewer
- Dementia or psychiatric illness which would preclude safe independent exercise.
- Acute untreated embolus/infarct.
- Dissecting aneurysm.
- Acute myocarditis or pericarditis.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Ireland1 site, 1 recruiting
- Recruiting
Beacon Hospital Dublin
Dublin
Aoife McGovern, +353 (01) 293 6600, Aoife.McGovern@beaconhospital.ie
About this study
Background to this Research Patients who undergo cancer treatment involving chemotherapy or immunotherapy, can experience considerable reductions in their fitness levels. This is a concern, as exercise is a really important part of cancer care. Therefore delivering exercise programmes that support patients during their chemotherapy or immunotherapy treatment will be essential to helping people to maintain their fitness levels. Research is needed to examine the best way to introduce exercise into the patient pathway in a way that is convenient and patient-centred.
The Specific Questions Being Asked This research project aims to examine the effect of an exercise programme which involves exercising on the cancer treatment day ward with a physiotherapist while waiting for treatment infusion as a safe and effective way of supporting patients to keep fit and active during chemotherapy treatment. The trial will also investigate if it the prescribed moderate intensity exercise for 30 minutes is manageable for patients.
Read more
Trial Plan This project will be delivered as a randomised controlled trial. All participants enrolled on the trial will receive information and advice about physical activity during chemotherapy treatment from a physiotherapist with expertise in cancer care. The intervention arm will also complete an exercise session with the physiotherapist on the day of their infusion treatment over a period of 12 weeks.
The feasibility of this protocol has already been tested in 17 participants with very positive results. The information gained from this initial study will be used to deliver this trial, which will recruit 80 participants. It is hoped that the information gained from this research will provide a practical way of providing supervised exercise training for patients during chemotherapy or immunotherapy that is safe, expert-led and patient centred.
Read the detailed description
Introduction
Cardiorespiratory fitness (CRF) is a critical health indicator that plays a significant role in predicting cancer risk and mortality. Notably, CRF often declines during infusion therapies such as chemotherapy and immunotherapy, and these declines may persist even after treatment completion. This reduction in CRF is concerning, as it may predispose patients to increased morbidity and mortality, especially given the cardiotoxic effects associated with some cancer treatments. Despite the importance of maintaining or improving CRF, the optimal timing and prescription for aerobic exercise in cancer care remain unclear. Current guidelines recommend that individuals with cancer aim for 150 minutes of moderate-intensity aerobic exercise weekly, or 75 minutes of vigorous-intensity exercise, along with twice-weekly resistance training. However, the prolonged periods of inactivity associated with infusion therapies, which often last several months, complicate adherence to these recommendations.
Aerobic exercise during cancer treatment has been shown to improve CRF, with systematic reviews indicating significant benefits in terms of physical function, fatigue reduction, and overall quality of life. Furthermore, exercise has been linked to improved cancer outcomes, including a reduced risk of cancer recurrence, lower cancer-specific mortality, and a decreased risk of all-cause mortality. Despite these benefits, adherence to exercise guidelines during cancer treatment remains low, with reports ranging from 8.5% to 34%. Barriers such as treatment side effects, fatigue, lack of knowledge, and time constraints often hinder patients from engaging in regular physical activity.
Recent studies suggest that supervised exercise performed immediately prior to infusion therapy may help mitigate these barriers, offering a structured and safe approach that could fit into patients' demanding treatment schedules. Additionally, there is emerging evidence that exercise performed during chemotherapy infusion could have beneficial physiological effects, such as improved tumour perfusion and enhanced drug delivery, potentially boosting the effectiveness of treatment. However, more research is needed to determine the optimal timing, duration, and intensity of exercise to achieve clinically meaningful benefits in this context.
As cancer incidence continues to rise, with approximately 44,000 new cancer cases reported annually in Ireland alone, the need for effective interventions that support patients during treatment is increasingly urgent. While exercise has demonstrated a range of physical, psychological, and immunological benefits, further investigation into the feasibility and impact of exercise during infusion therapy is essential to guide clinical practice. This protocol aims to address common barriers to exercise for cancer patients, based on recent systematic reviews and patient input, with the goal of enhancing patient care and outcomes through improved maintenance of CRF during treatment.
Aims and Objectives
The overall aim of this study is to examine the feasibility of delivering a supervised moderate intensity aerobic exercise intervention to patients with cancer directly before their infusion therapy.
The specific objectives are:
To determine the rate of recruitment of cancer patients willing to participate in the exercise programme during chemotherapy.
To examine the feasibility of intervention delivery, including exercise adherence, fidelity, and retention rates.
To examine if supervised moderate intensity aerobic exercise directly before infusion therapy increases and or maintains cardiorespiratory fitness in cancer patients to a greater extent than education alone.
To test the appropriateness of outcome assessments, data collection techniques, and suitability of proposed outcomes.
To monitor and record any adverse events to test the safety of the exercise intervention.
To gather feedback from patients regarding the acceptability of the exercise programme.
To examine the preliminary efficacy of the exercise programme on secondary endpoints such as fatigue, physical activity levels and quality of life.
- Conditions
- Cancer
- Being tested
- Exercise
- Keywords
- exercise, cardiorespiratory fitness, chemotherapy, exercise oncology
- Medical subject headings
- Neoplasms, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ExerciseBehavioural
The exercise programme will be prescribed at a moderate intensity (Target Heart rate: 60%-65% Heart Rate Reserve + resting heart rate) for 30 minutes immediately prior to infusion therapy, on their treatment days over 12- weeks. Exercise will be completed on a stationary cycle ergometer. Target heart rate will be adjusted to 50-55% Heart Rate Reserve + resting heart rate if patient is complaining of fatigue/nausea, is on beta-blockers or if haemoglobin <9g/dL. Heart rate monitoring by chest strap using the polar heart rate monitor will allow participants to self-regulate their exercise intensity. Participants should discontinue exercise and await medical review if they develop chest pain, dizziness or pre-syncope, cyanosis or pallor appearance, new musculoskeletal pain.
| Study group | Role | What they receive |
|---|---|---|
| Exercise Arm | Experimental | The exercise programme will be prescribed at a moderate intensity (Target Heart rate: 60%-65% Heart Rate Reserve + resting heart rate) for 30 minutes immediately prior to infusion therapy, on their treatment days over 12- weeks. Exercise will be completed on a stationary cycle ergometer. Target heart rate will be adjusted to 50-55% Heart Rate Reserve + resting heart rate if patient is complaining of fatigue/nausea, is on beta-blockers or if haemoglobin <9g/dL. Heart rate monitoring by chest strap using the polar heart rate monitor will allow participants to self-regulate their exercise intensity. Participants should discontinue exercise and await medical review if they develop chest pain, dizziness or pre-syncope, cyanosis or pallor appearance, new musculoskeletal pain. Receives: Behavioral: Exercise |
| Education only | No intervention | The control group will receive education on the physical activity recommendations during cancer treatment as per standard care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility - Recruitment Rates
Recruitment rates will be calculated as the percentage of eligible participants who agreed to take part in the study. Recruitment rates will be calculated for each recruitment timepoint to determine which timepoint yields optimal recruitment. Reasons for declining recruitment will also be recorded.
Measured: Enrolment (baseline)
Feasibility - Adherence Rates
Exercise adherence will be used to measure the degree to which the participants performed the exercise at the desired intensity and time. After each exercise session, participants will be asked to rate their perceived exertion that they actually achieved during the exercise session. This RPE will be compared to the moderate intensity (BORG 4-6) intensity prescribed to determine adherence to intensity. Heart rate data recorded during the exercise session will also be compared with target heart rate prescribed to assess adherence to intensity. The Adherence to exercise time will be calculated by recording the total number of minutes spent cycling in each session compared to the 30 minute cycling target.
Measured: Weeks 1 to 12
Feasibility - Retention Rates
Retention rates will be calculated as the number of participants completing the post intervention assessment. Reasons for dropout will also be recorded.
Measured: Post-intervention (12 weeks)
Feasibility - Satisfaction
Qualitative data will be used to analyse the overall delivery of the exercise programme and suitability of intervention characteristics. Qualitative data will be collected using satisfaction questionnaires.
Measured: Post intervention (12 weeks)
Secondary outcomes (6)
Cardiorespiratory Fitness
CPETs will be performed on a cycle ergometer (h/p Cosmos model Cosmed E100) in the exercise physiology laboratory in the Beacon Orthopaedic Centre under the supervision of two exercise physiologists. The VO2peak test will be conducted on a cycle ergometer connected to the COSMED software. A standardised incremental ramp protocol will be used, commencing with a 2-minute phase of unloaded cycling. Followed by the ramped exercise phase with increases in workload (watts) to exhaustion in approximately 8-15 minutes for each individual. During CPET, Borg RPE scores will be recorded every 2 minutes and COSMED software captured the physiological measures from the breath-by-breath gas analyser with continuous monitoring of ventilation, carbon dioxide production, oxygen consumption and heart rate.
Measured: Baseline & 12 weeks
Body composition - Anthropometric measures
Weight (kilogrammes (kg)) and height (centimetres (cm)) will be recorded by standard methods using a calibrated scales and stadiometer (Seca 704 S Wireless Column Scale With Integrated Measuring Rod). Body mass index (BMI) will be calculated as weight (kg) divided by height (metres (m2)).
Measured: Baseline & 12 weeks
Body Composition - Air Displacement Plethysmography (ADP)
ADP will be used to determine body composition and will be performed using the 'Bod Pod'. Outputs from the Bod Pod provide multiple metrics of body composition. Measures recorded will include; fat mass, fat free mass, and skeletal muscle mass.
Measured: Baseline & 12 weeks
Health Related Quality of Life
Health-related quality of life will be determined by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30 version 3.0) and its relevant subscales. The EORTC-QLQ-C30 manual advises that all of the scales and single item measures range in score from 0 to 100. A high score for the functional scales and functional single items represents a high/healthy level of functioning, whereas a high score for the symptom scales and symptom item represents a high level of symptom burden or problems.
Measured: Baseline & 12 weeks
Fatigue
Fatigue will be measured using the Brief Fatigue Inventory (BFI). The BFI is a 9-item scale to assess the severity of fatigue and the impact of fatigue on daily functioning in the past 24 hours. BFI scoring guidance categorises fatigue as mild (1-3), moderate (4-6), or severe (7-10), based on a global score calculated as the average of the nine items, where 0 is no fatigue and 10 is the worst possible fatigue or complete interference. A score of 4 or greater indicates a need for intervention, and scores of 7-10 represent severe fatigue
Measured: Baseline & 12 weeks
Physical Activity Levels
Participants self-reported physical activity levels will be recorded using The International Physical Activity Questionnaire - Short Form (IPAQ-SF). The IPAQ-SF is a 7 item open ended questionnaire on an individuals physical activity in the last 7 days. The IPAQ-SF scoring protocol involves calculating a total score in MET-minutes/week by combining walking, moderate, and vigorous activity durations, then categorising the score into low (< 600), moderate (600-3,000), or high (> 3,000 MET-minutes/week) levels
Measured: Baseline & 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2025
- Study start24 Sep 2025
- Primary completionSep 2026 (estimated)
- Study completionSep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Dublin, Trinity College
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Emer Guinan, University of Dublin, Trinity College
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07182773
- Sponsor's protocol ID
- TRI CRF 24-02
- Other IDs
- AHP24MCG
- Acronym
- PACE-CRC
- Status last verified
- Aug 2025
- First submitted
- 5 Sep 2025
- Last updated
- 4 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Kearney N, Connolly D, Begic S, Mockler D, Guinan E. Feasibility metrics of exercise interventions during chemotherapy: A systematic review. Crit Rev Oncol Hematol. 2024 Mar;195:104272. doi: 10.1016/j.critrevonc.2024.104272. Epub 2024 Jan 23.
PubMed 38272152
Study at a glance
From the registry record, last updated by the sponsor on 4 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pre-infusion Aerobic Cycling Exercise for CardioRespiratory Fitness in Cancer Patients
- ClinicalTrials.gov ID
- NCT07182773
- Acronym / sponsor ID
- PACE-CRC / TRI CRF 24-02
- Conditions
- Cancer
- Keywords
- exercise, cardiorespiratory fitness, chemotherapy, exercise oncology
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- University of Dublin, Trinity CollegeUniversity, hospital or other
- Study start
- 24 Sep 2025 (actual)
- Primary completion
- Sep 2026 (estimated)
- Study completion
- Sep 2027 (estimated)
- First posted
- 19 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background to this Research Patients who undergo cancer treatment involving chemotherapy or immunotherapy, can experience considerable reductions in their fitness levels. This is a concern, as exercise is a really important part of cancer care. Therefore delivering exercise programmes that support patients during their chemotherapy or immunotherapy treatment will be essential to helping people to maintain their fitness levels. Research is needed to examine the best way to introduce exercise into the patient pathway in a way that is convenient and patient-centred.
The Specific Questions Being Asked This research project aims to examine the effect of an exercise programme which involves exercising on the cancer treatment day ward with a physiotherapist while waiting for treatment infusion as a safe and effective way of supporting patients to keep fit and active during chemotherapy treatment. The trial will also investigate if it the prescribed moderate intensity exercise for 30 minutes is manageable for patients.
Trial Plan This project will be delivered as a randomised controlled trial. All participants enrolled on the trial will receive information and advice about physical activity during chemotherapy treatment from a physiotherapist with expertise in cancer care. The intervention arm will also complete an exercise session with the physiotherapist on the day of their infusion treatment over a period of 12 weeks.
The feasibility of this protocol has already been tested in 17 participants with very positive results. The information gained from this initial study will be used to deliver this trial, which will recruit 80 participants. It is hoped that the information gained from this research will provide a practical way of providing supervised exercise training for patients during chemotherapy or immunotherapy that is safe, expert-led and patient centred.
Detailed description
Introduction
Cardiorespiratory fitness (CRF) is a critical health indicator that plays a significant role in predicting cancer risk and mortality. Notably, CRF often declines during infusion therapies such as chemotherapy and immunotherapy, and these declines may persist even after treatment completion. This reduction in CRF is concerning, as it may predispose patients to increased morbidity and mortality, especially given the cardiotoxic effects associated with some cancer treatments. Despite the importance of maintaining or improving CRF, the optimal timing and prescription for aerobic exercise in cancer care remain unclear. Current guidelines recommend that individuals with cancer aim for 150 minutes of moderate-intensity aerobic exercise weekly, or 75 minutes of vigorous-intensity exercise, along with twice-weekly resistance training. However, the prolonged periods of inactivity associated with infusion therapies, which often last several months, complicate adherence to these recommendations.
Aerobic exercise during cancer treatment has been shown to improve CRF, with systematic reviews indicating significant benefits in terms of physical function, fatigue reduction, and overall quality of life. Furthermore, exercise has been linked to improved cancer outcomes, including a reduced risk of cancer recurrence, lower cancer-specific mortality, and a decreased risk of all-cause mortality. Despite these benefits, adherence to exercise guidelines during cancer treatment remains low, with reports ranging from 8.5% to 34%. Barriers such as treatment side effects, fatigue, lack of knowledge, and time constraints often hinder patients from engaging in regular physical activity.
Recent studies suggest that supervised exercise performed immediately prior to infusion therapy may help mitigate these barriers, offering a structured and safe approach that could fit into patients' demanding treatment schedules. Additionally, there is emerging evidence that exercise performed during chemotherapy infusion could have beneficial physiological effects, such as improved tumour perfusion and enhanced drug delivery, potentially boosting the effectiveness of treatment. However, more research is needed to determine the optimal timing, duration, and intensity of exercise to achieve clinically meaningful benefits in this context.
As cancer incidence continues to rise, with approximately 44,000 new cancer cases reported annually in Ireland alone, the need for effective interventions that support patients during treatment is increasingly urgent. While exercise has demonstrated a range of physical, psychological, and immunological benefits, further investigation into the feasibility and impact of exercise during infusion therapy is essential to guide clinical practice. This protocol aims to address common barriers to exercise for cancer patients, based on recent systematic reviews and patient input, with the goal of enhancing patient care and outcomes through improved maintenance of CRF during treatment.
Aims and Objectives
The overall aim of this study is to examine the feasibility of delivering a supervised moderate intensity aerobic exercise intervention to patients with cancer directly before their infusion therapy.
The specific objectives are:
To determine the rate of recruitment of cancer patients willing to participate in the exercise programme during chemotherapy.
To examine the feasibility of intervention delivery, including exercise adherence, fidelity, and retention rates.
To examine if supervised moderate intensity aerobic exercise directly before infusion therapy increases and or maintains cardiorespiratory fitness in cancer patients to a greater extent than education alone.
To test the appropriateness of outcome assessments, data collection techniques, and suitability of proposed outcomes.
To monitor and record any adverse events to test the safety of the exercise intervention.
To gather feedback from patients regarding the acceptability of the exercise programme.
To examine the preliminary efficacy of the exercise programme on secondary endpoints such as fatigue, physical activity levels and quality of life.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Exercise Arm | Experimental | Behavioral: ExerciseThe exercise programme will be prescribed at a moderate intensity (Target Heart rate: 60%-65% Heart Rate Reserve + resting heart rate) for 30 minutes immediately prior to infusion therapy, on their treatment days over 12- weeks. Exercise will be completed on a stationary cycle ergometer. Target heart rate will be adjusted to 50-55% Heart Rate Reserve + resting heart rate if patient is complaining of fatigue/nausea, is on beta-blockers or if haemoglobin <9g/dL. Heart rate monitoring by chest strap using the polar heart rate monitor will allow participants to self-regulate their exercise intensity. Participants should discontinue exercise and await medical review if they develop chest pain, dizziness or pre-syncope, cyanosis or pallor appearance, new musculoskeletal pain. |
| Education only | No intervention | –The control group will receive education on the physical activity recommendations during cancer treatment as per standard care |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Aged >18.
- Histological confirmed diagnosis of stage I to IIIc breast, ovarian, or colorectal cancer.
- Scheduled to receive chemotherapy ± immunotherapy with curative intent over at least a 12-week period.
- Medical clearance from oncologist to partake in regular exercise in accordance with ACSM preparticipation screening algorithm.
- Able to use exercise bike independently.
Key exclusion criteria (10 listed)
- Advanced/metastatic disease.
- Scheduled to receive concurrent chemoradiotherapy.
- New pain or other pain that would preclude ability to use bike.
- Inability to read and understand English.
- Deemed unfit to proceed from results of CPET.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ExerciseThe exercise programme will be prescribed at a moderate intensity (Target Heart rate: 60%-65% Heart Rate Reserve + resting heart rate) for 30 minutes immediately prior to infusion therapy, on their treatment days over 12- weeks. Exercise will be completed on a stationary cycle ergometer. Target heart rate will be adjusted to 50-55% Heart Rate Reserve + resting heart rate if patient is complaining of fatigue/nausea, is on beta-blockers or if haemoglobin <9g/dL. Heart rate monitoring by chest strap using the polar heart rate monitor will allow participants to self-regulate their exercise intensity. Participants should discontinue exercise and await medical review if they develop chest pain, dizziness or pre-syncope, cyanosis or pallor appearance, new musculoskeletal pain. | Behavioural | Exercise Arm |
Primary outcome
Feasibility - Recruitment Rates
Time frame: Enrolment (baseline)
Recruitment rates will be calculated as the percentage of eligible participants who agreed to take part in the study. Recruitment rates will be calculated for each recruitment timepoint to determine which timepoint yields optimal recruitment. Reasons for declining recruitment will also be recorded.
Feasibility - Adherence Rates
Time frame: Weeks 1 to 12
Exercise adherence will be used to measure the degree to which the participants performed the exercise at the desired intensity and time. After each exercise session, participants will be asked to rate their perceived exertion that they actually achieved during the exercise session. This RPE will be compared to the moderate intensity (BORG 4-6) intensity prescribed to determine adherence to intensity. Heart rate data recorded during the exercise session will also be compared with target heart rate prescribed to assess adherence to intensity. The Adherence to exercise time will be calculated by recording the total number of minutes spent cycling in each session compared to the 30 minute cycling target.
Feasibility - Retention Rates
Time frame: Post-intervention (12 weeks)
Retention rates will be calculated as the number of participants completing the post intervention assessment. Reasons for dropout will also be recorded.
Feasibility - Satisfaction
Time frame: Post intervention (12 weeks)
Qualitative data will be used to analyse the overall delivery of the exercise programme and suitability of intervention characteristics. Qualitative data will be collected using satisfaction questionnaires.
6 secondary outcomes
Cardiorespiratory Fitness
Time frame: Baseline & 12 weeks
Body composition - Anthropometric measures
Time frame: Baseline & 12 weeks
Body Composition - Air Displacement Plethysmography (ADP)
Time frame: Baseline & 12 weeks
Health Related Quality of Life
Time frame: Baseline & 12 weeks
Fatigue
Time frame: Baseline & 12 weeks
Physical Activity Levels
Time frame: Baseline & 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 May 2026.
- Results publication: PubMed 38272152Kearney N, Connolly D, Begic S, Mockler D, Guinan E. Feasibility metrics of exercise interventions during chemotherapy: A systematic review. Crit Rev Oncol Hematol. 2024 Mar;195:104272. doi: 10.1016/j.critrevonc.2024.104272. Epub 2024 Jan 23.
- Individual participant dataSharing planned: No
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Exercise in people with Cancer, run by University of Dublin, Trinity College at 1 site in Ireland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Ireland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Aoife McGovern (+3531 293 6692, physiotherapy@beaconhospital.ie), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility - Recruitment Rates (time frame: Enrolment (baseline)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07182773, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2026.